← C&S Paper overview

C&S Paper vs Colgate-Palmolive: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

C&S Paper Co Ltd (002511.CS)

Colgate-Palmolive Company (CL)

Q3 2026
▼3▲1

Colgate's strong Q2 offset by weak U.S. demand and index removal

  • Q2 earnings beat and raised guidance Colgate's second-quarter profit beat expectations and management raised its full-year outlook. Gross margin expanded to 61.5%, free cash flow margin neared 18%, and the dividend rose for the 63rd straight year.

    This is the main positive force behind the stock's year-to-date gain.

  • U.S. volumes weak as shoppers trade down U.S. sales volumes are flat or falling as shoppers switch to cheaper store-brand products. North America consumption dropped about 1% and shipments fell about 3%, with management calling the U.S. performance unsatisfactory.

    This is the biggest drag on the stock and a key risk to future growth.

  • Tariff and raw material cost pressures Rising tariffs and raw material costs are clouding Colgate's profit outlook. These higher expenses could squeeze margins if the company cannot raise prices enough to offset them.

    This is a new cost headwind that threatens profitability.

  • Removal from S&P 100 forced index selling Colgate was removed from the S&P 100 index, which forced index-tracking funds to sell the stock. This technical selling pressure weighed on the share price during the period.

    This is a specific event that created downward pressure on the stock.

August 2026
▼3▲1

Colgate's strong Q2 offset by weak U.S. demand and index removal

  • Q2 earnings beat and raised guidance Colgate's second-quarter profit beat expectations and management raised its full-year outlook. Gross margin expanded to 61.5%, free cash flow margin neared 18%, and the dividend rose for the 63rd straight year.

    This is the main positive force behind the stock's year-to-date gain.

  • U.S. volumes weak as shoppers trade down U.S. sales volumes are flat or falling as shoppers switch to cheaper store-brand products. North America consumption dropped about 1% and shipments fell about 3%, with management calling the U.S. performance unsatisfactory.

    This is the biggest drag on the stock and a key risk to future growth.

  • Tariff and raw material cost pressures Rising tariffs and raw material costs are clouding Colgate's profit outlook. These higher expenses could squeeze margins if the company cannot raise prices enough to offset them.

    This is a new cost headwind that threatens profitability.

  • Removal from S&P 100 forced index selling Colgate was removed from the S&P 100 index, which forced index-tracking funds to sell the stock. This technical selling pressure weighed on the share price during the period.

    This is a specific event that created downward pressure on the stock.

Latest
▲2▼1

Colgate's profit engine hums, but U.S. shoppers stay cautious

  • Margins and cash flow stay elite Colgate's gross margin is about 60%, free cash flow margin near 18%, and Q2 gross margin expanded to 61.5%. Management raised 2026 gross margin guidance to roughly flat and lifted EPS growth outlook to mid-single digits. Strong cash generation supports dividends and buybacks, underpinning the stock.

    Shows the core financial strength that supports CL's valuation despite slow growth.

  • U.S. demand weak, competition intense North America consumption fell about 1% and shipments dropped roughly 3% in Q2 as shoppers bought less and retailers cut stock. CEO called U.S. performance unsatisfactory. This limits growth in Colgate's home market and pressures pricing power, a key drag on the stock.

    Identifies the main operational weakness weighing on CL's growth outlook.

  • Dividend streak extended, income appeal Colgate raised its quarterly dividend to $0.53, marking 63 straight years of increases, and declared the next payment. The stock has outperformed the S&P 500 in 2026 with about a 20% gain. Reliable income and a long track record attract investors, supporting the share price.

    Highlights the shareholder return that makes CL attractive to income-focused investors.

  • Premium innovation push to revive growth Colgate is boosting advertising and premium oral care products like Optic White Pro Series to spark a North America recovery. Management expects gradual improvement but warns it won't be smooth. Higher spending could lift sales, but may squeeze margins if demand stays soft.

    Explains the key strategic bet that will determine whether CL reaccelerates growth.

▼2

Colgate beats on earnings but tariffs, weak volumes and index exit weigh

  • Q2 earnings beat, guidance raised, but tariff costs cloud outlook Colgate beat profit and sales estimates, with margins expanding and full-year earnings guidance raised. But management flagged rising tariff costs and raw materials, and the stock fell 1.8% on the day. The market is weighing solid results against cost pressures ahead.

    This is the core earnings event that sets the tone for the period and explains the mixed price reaction.

  • U.S. volumes flat as shoppers switch to cheaper store brands Colgate's U.S. sales volumes were flat or falling as shoppers trade down to private-label and newer brands. This squeezes growth in its home market and pressures pricing power. It's a broad industry problem, but it directly limits how fast Colgate can grow.

    This demand weakness is a key reason the stock struggles despite the earnings beat.

  • Removed from S&P 100 index, forcing some funds to sell Colgate is being dropped from the S&P 100 index, which means index-tracking funds must sell their shares. That creates mechanical selling pressure around the change date. It doesn't reflect the business itself, but it can push the price down in the short term.

    This is a concrete, new event that adds selling pressure on the stock.

  • Exploring sale of Softsoap, Irish Spring and other personal care brands Colgate is reportedly working with Goldman Sachs to sell some mass-market personal care brands, potentially raising over $1 billion. Selling slower-growing brands could sharpen focus on core oral care, but it also means giving up revenue. The net effect on the stock is unclear.

    This is a major strategic move that could reshape the company and is the latest news in the period.